Innovation in Medical-Legal Regulatory Review: Improving Quality and Efficiency in Pharmaceutical Product Approvals
Main Article Content
Abstract
Approval of pharmaceutical products hinges on evaluating clinical evidence, the benefit-risk profile in product labeling, the consistency of labeling information with claims, and the appropriate legal framing of product claims. In typical review processes where each factor is treated sequentially during the approval pathway, delays, iterative cycles, and inconsistencies become the norm, hampering patient access and driving up costs. This paper describes several practical methods for redesigning clinical review to reduce inefficiency and enhance quality by: involving medical expertise and legal perspective earlier in the process, leveraging structured decision tools, utilizing targeted digital tools such as text analysis in reviewing content against claims for consistency, and identifying and mitigating core risk points of inefficiency and error within review. The paper reviews innovative approaches already adopted by companies and regulatory agencies, proposes a conceptually organized, integrated, and modular approach that engages medical and legal expertise from the outset, and identifies specific measures of value (e.g., accelerated review cycles, improved label quality) that the framework should provide while upholding high standards for patient safety and legal robustness. The paper discusses concrete implementation steps, meaningful metrics, and persistent challenges to guide industry and regulatory reviewers.
Article Details
Section
How to Cite
References
1. Arlett, P., Ehmann, F., Herold, R., Korakianiti, E., Moscariello, P., Barbier, L., Gravanis, I., Pétavy, F., Cormier, E., Thomson, A., Vamvakas, S., & Thirstrup, S. (2025). A fast path from innovation to safe and effective medicines. Clinical Pharmacology & Therapeutics, 118(6), 1392–1404. https://doi.org/10.1002/cpt.70107
2. Centre for Innovation in Regulatory Science. (2025). CIRS R&D briefing 101: New drug approvals in ICH countries 2015–2024. https://cirsci.org
3. Council for International Organizations of Medical Sciences. (2025). Benefit-risk balance for medicinal products: Report of the CIOMS Working Group XII. CIOMS.
4. Dilek, S., Woods, R. H., Ballreich, J., Moore, T. J., & Alexander, G. C. (2026). Deficiencies delaying prescription drug approvals by the U.S. Food and Drug Administration, 2020–2024. Therapeutic Innovation & Regulatory Science, 60, 837–846. https://doi.org/10.1007/s43441-026-00921-3
5. Gray, M., Xu, J., Tong, W., & Wu, L. (2023). Classifying free texts into predefined sections using AI in regulatory documents: A case study with drug labeling documents. Chemical Research in Toxicology, 36(8), 1290–1299.
6. Hammad, T. A., Sabrdaran, S., & Heim, J. M. (2024). Achieving synchrony: Bridging the gap between pharmaceutical companies and regulators on safety labeling updates. Frontiers in Drug Safety and Regulation, 4, Article 1477516.
7. International Council for Harmonisation. (2009). Q10: Pharmaceutical quality system. https://database.ich.org/sites/default/files/Q10%20Guideline.pdf
8. International Council for Harmonisation. (2017). M4E(R2): The common technical document for the registration of pharmaceuticals for human use – Efficacy. https://database.ich.org/sites/default/files/M4E_R2__Guideline.pdf
9. International Council for Harmonisation. (2019). Q12: Technical and regulatory considerations for pharmaceutical product lifecycle management. https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf
10. Lackey, L., Thompson, G., & Eggers, S. (2021). FDA’s benefit–risk framework for human drugs and biologics: Role in benefit–risk assessment and analysis of use for drug approvals. Therapeutic Innovation & Regulatory Science, 55(1), 170–179. https://doi.org/10.1007/s43441-020-00203-6
11. Martin, J. D., Frear, D., Roberts, S. A., Dohnal, V. A., Kieffer, C., Morin, S. L., ... & Chhina, N. (2025). Patient experience data (PED) in 2019–2023 US FDA NME drug approvals: Analysis and recommendations. Therapeutic Innovation & Regulatory Science, 59(4), 859–870.
12. O’Donnell, K., & Kartoglu, U. (2026). QRM, knowledge management, and the importance of ICH Q9(R1). Pharmaceutical Technology.
13. Sacks, L. V., Shamsuddin, H. H., Yasinskaya, Y. I., Bouri, K., Lanthier, M. L., & Sherman, R. E. (2014). Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000–2012. JAMA, 311(4), 378–384. https://doi.org/10.1001/jama.2013.282542
14. Schlafender Hase. (2026). Biotech labeling workflow: Where it breaks down and how to fix it. https://schlafenderhase.com/articles/biotech-labeling-workflow/
15. Simonetti, A., Colilla, S., Edwards, B., Kübler, J., Lackey, L., Rodriguez, L., Talbot, S., Yang, H., Wang, W., Williams, D., & Higginson, J. M. (2024). Key opinion leaders’ interviews to inform the future of benefit–risk planning in the medical total product life cycle of global pharmaceutical and medical device organizations. Drug Safety, 47(9), 853–868. https://doi.org/10.1007/s40264-024-01442-4
16. U.S. Food and Drug Administration. (2023). Benefit-risk assessment for new drug and biological products: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/benefit-risk-assessment-new-drug-and-biological-products
17. Vokinger, K. N., Serra-Burriel, M., Glaus, C. E. G., Welti, L., Ross, J. S., & Kesselheim, A. S. (2025). Differences between trial populations and approved label populations of new drugs in the United States and Europe (2012 to 2023): A cross-sectional study. Annals of Internal Medicine, 178(8), 1127–1137. https://doi.org/10.7326/ANNALS-24-03242
18. Zhou, Q., Zhou, Z., Johnson, M., Ngo, M., Ferrari, F., & Ma, J. (2025). ClinicalRAG: Automating pharmaceutical label quality control with hierarchical RAG and large language models. Proceedings of the AAAI Conference on Artificial Intelligence.